Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)
Zenocutuzumab offers meaningful and durable antitumor activity, substantially reduced toxicity and no treatment‑limiting safety concerns, distinguishing it favorably from existing standards of careLEXINGTON, Mass., July 2, 2026 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology…
News provided by PR Newswire.
